Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2000-01-10
2003-08-19
Kemmerer, Elizabeth (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S007100, C435S007230, C435S007400, C435S007920, C435S188000, C435S219000, C435S226000
Reexamination Certificate
active
06607894
ABSTRACT:
This application claims priority to international patent application Ser. No. PCT/AU98/000189, filed Mar. 20, 1998, and to Australian patent application PO 5736, filed Mar. 20, 1997.
This invention relates to methods for detection of cancer, and in particular to the detection of endometrial cancer. The method of the invention is amenable to large-scale screening, for example in women at increased risk of endometrial cancer.
BACKGROUND OF THE INVENTION
It is now clear that in many malignancies there is a high correlation between tumour aggressiveness and protease expression by the tumour cells. In the last seven years, for example, convincing evidence has accumulated that directly implicates members of the matrix metalloproteinase family in tumour invasion and metastasis.
Clinicians have long been aware of the need for developing objective criteria for the early detection of cancer, and for assessing prognostic factors when treating patients who have a malignant tumour. In general the stage of endometrial cancer, the degree of invasion into the myometrium, the histological grade and type of tumour, and the degree of invasion of the lymph-vascular space have some predictive value as to the aggressiveness of the disease. However, none of these factors is accurate, and all depend on subjective assessment. For example the type and grade of tumour are determined by histological examination, and it has been reported that assessment of these may result in a disagreement figure of up to 85% between individual different pathologists (Baak and Oort, 1991). Thus currently there is no means of predicting the prognosis for an individual patient.
It is becoming clear that the accurate prediction of the course of endometrial cancer, and the probability of survival following various types of treatment, also depend on the intrinsic properties of the malignant cells and their interaction with the host (Baak, 1991). A major objective of research in this field, therefore, is to discover the biological properties that determine the tumour's invasive and metastatic potential.
It is known from studies with other types of cancer that quantitative techniques related to tumour cell biology, such as DNA ploidy (Iversen, 1986; van der Putten et al, 1989; Berchuck et al, 1992; Podratz et al, 1993; Lukes et al, 1994), expression of E-cadherin which mediates cell-cell adhesion (Sakuragi et al, 1994), and the secretion of matrix metalloproteinases (MMPs) involved in cell invasion (Liotta et al, 1986; Stetler-Sevenson et al, 1993) can improve the assessment of prognosis and the prediction of survival, by providing reproducible objective measures related to the behaviour of the neoplastic cells. Alterations in cellular DNA content (ploidy) have been shown to correlate with biological behaviour in cancers of the ovary, breast, colon, lung and prostate (Seckinger et al, 1989), as well as in uterine malignancies (Moberger et al, 1985; van der Putten et al, 1989). In general, cancers with a normal diploid DNA content have a better prognosis than cancers with an abnormal, aneuploid or polyploid DNA content. Determination of DNA ploidy in endometrial and other cancers has therefore become a powerful tool for assessing prognosis and the probability of survival in relation to recurrence of the disease, and is a better predictor than molecular or genetic markers (Lukes et al, 1994).
It is now clear that in many malignancies there is a high correlation between tumour aggressiveness and expression of proteases in the tumour tissue. In the last seven years, for example, convincing evidence has accumulated that directly implicates members of the matrix metalloproteinase (MMP) family and tissue inhibitors of metalloproteinases (TIMPs) in tumour invasion and metastasis (reviewed by Stetler-Stevenson et al, 1993). It has been suggested that detection of MMPs in biological fluids, especially as complexes with TZMPs, can be used to detect metastatic cancer (U.S. Pat. No 5,324,634 by Zucker). These enzymes are also synthesised and secreted by normal cells during physiological tissue remodelling (menstruation) and invasion (embryo implantation) (Salamonsen, 1995, 1996). MMPs may be present in tissues either in the fully active form, or in a latent form which requires activation before enzymic activity can be demonstrated.
We have recently established that MMPs are released into the uterine cavity during the ovarian cycle and early pregnancy in marmoset monkeys (our unpublished results). Moreover, over-expression of these enzymes has been reported to occur in many tumour cells, for example those of colorectal and squamous cell carcinomas.
Recently it has been demonstrated that ovarian cancer cells, but not normal ovarian epithelial cells, secrete enhanced levels of matrix metalloproteinases similar to MMP-2 and MMP-9, which directly degrade basement membrane proteins (Moser et al, 1994; Salamonsen, 1996). This proteolytic capability was correlated with the invasive potential of the ovarian malignancies. Furthermore, immunohistochemistry employing monoclonal antibodies has been used to localize MMP-2 to the cytoplasm and plasma membranes of various neoplastic cells, including endometrial cancers, whereas TIMP-2 was localized mainly to the stroma of these tissues (Hoyhtya et al, 1994). Apart from this, little is known about the expression of HMPs and TIMPs in endometrial cancers. Such information is essential for developing strategies for controlling the biological behaviour of endometrial and other types of malignancies.
We have now unexpectedly discovered that matrix metalloproteinases can be detected in uterine washings from patients with endometrial cancer, but not in similar washings from control women. This finding makes possible a sensitive diagnostic test which can be performed with minimal invasion, and a screening test which may be utilised for screening at-risk populations or the general population, or for use in clinical trials of putative treatments. The test is also suitable for monitoring the efficacy of treatment and for detection of recurrences.
SUMMARY OF THE INVENTION
In one aspect, the invention provides a method of assaying for the presence and/or risk of endometrial cancer, comprising the steps of obtaining a sample of uterine washings from a subject at risk of, or suspected to be suffering from, endometrial cancer, and measuring the levels of matrix metalloproteinases (MMPs) in the washings.
For the purposes of this specification, the expression “detection of endometrial cancer” is used in its broadest sense, and includes the determination of the likely presence or absence of cancer, or cells in a precancerous state or the early phases of development of cancer. Thus the invention encompasses not only the detection of active endometrial cancer, but also the risk of developing such active cancer.
The uterine washings may be obtained by using any suitable solution which is delivered to the uterine cavity and then recovered and collected for testing. Suitable solutions will be readily apparent to those skilled in the art and include any sterile non-toxic solution which will not interfere with measurement of MMPs. An example of a suitable solution is sterile saline. Any number of means for delivery and recovery of the washing solution may be utilised, by way of example a syringe and tube are conveniently used. The washing may be collected in the recovery means or transferred to another container. Delivery, recovery and collection means will routinely be chosen to provide comfort and convenience to both the patient and clinician.
Any suitable technique for determining levels of MMPs in the washings may be employed in the method of the invention. Examples of suitable techniques include those based on determining enzyme activity, and/or those based on determining the presence or levels of enzyme. Total MMPs, including latent, active, and TIMP-bound MMP, may be measured. Those skilled in the art will readily be able to determine whether or not a technique is suitable, if necessary using positive and negative contr
Lopata Alexander
Quinn Michael A.
Salamonsen Lois A.
DeConti, Jr. Esq. Giulio A.
Kemmerer Elizabeth
Lahive & Cockfield LLP
Lauro, Esq. Peter C.
LandOfFree
Matrix metalloproteinase levels as indicators of endometrial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Matrix metalloproteinase levels as indicators of endometrial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matrix metalloproteinase levels as indicators of endometrial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3119949